ArticleProceedings of the National Academy of Sciences of the United States of America1994
Transphosphorylation as the mechanism by which the high-affinity receptor for IgE is phosphorylated upon aggregation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 195 citations in OpenAlex.
- Review
- Anti-microbial cetylpyridinium chloride suppresses mast cell function by targeting tyrosine phosphorylation of Syk kinase.Journal of immunotoxicology · 2024Article
- IgE versus IgG and IgA: Differential roles of allergen-specific antibodies in sensitization, tolerization, and treatment of allergies.Immunological reviews · 2024Review
- Article
- Article
- Scrodentoid A Inhibits Mast Cell-Mediated Allergic Response by Blocking the Lyn-FcεRIβ Interaction.Frontiers in immunology · 2019Article
- Interaction of DJ-1 with Lyn is essential for IgE-mediated stimulation of human mast cells.The Journal of allergy and clinical immunology · 2018Article
- BIOPYDB: A Dynamic Human Cell Specific Biochemical Pathway Database with Advanced Computational Analyses Platform.Journal of integrative bioinformatics · 2018Article
- Positive and Negative Regulatory Roles of C-Terminal Src Kinase (CSK) in FcεRI-Mediated Mast Cell Activation, Independent of the Transmembrane Adaptor PAG/CSK-Binding Protein.Frontiers in immunology · 2018Article
- Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old.Advances in protein chemistry and structural biology · 2018Review
- Functional nanoscale coupling of Lyn kinase with IgE-FcεRI is restricted by the actin cytoskeleton in early antigen-stimulated signaling.Molecular biology of the cell · 2016Article
- Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.The Journal of experimental medicine · 2015Article
- Transmembrane adaptor protein PAG/CBP is involved in both positive and negative regulation of mast cell signaling.Molecular and cellular biology · 2014Article
- Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.Journal of leukocyte biology · 2014Article
- Rethinking the role of immunoglobulin E and its high-affinity receptor: new insights into allergy and beyond.International archives of allergy and immunology · 2014Review
- The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Novel PKCα-mediated phosphorylation site(s) on cofilin and their potential role in terminating histamine release.Molecular biology of the cell · 2012Article
- Quantitative nanoscale analysis of IgE-FcεRI clustering and coupling to early signaling proteins.The journal of physical chemistry. B · 2012Article
- A mechanistic model of early FcεRI signaling: lipid rafts and the question of protection from dephosphorylation.PloS one · 2012Article
- The Fyn-STAT5 Pathway: A New Frontier in IgE- and IgG-Mediated Mast Cell Signaling.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When aggregated, the high-affinity receptors for IgE on mast cells (Fc epsilon RI) launch a series of phosphorylations, particularly of protein tyrosines. We have analyzed how aggregation initiates this cascade. We examined Fc epsilon RI from unstimulated cells and from cells exposed to a polyvalent hapten conjugate that aggregates the Fc epsilon RI via the receptor-bound anti-hapten IgE. We also examined the latter receptors after they had been disaggregated in vitro with monovalent hapten. By an in vitro kinase assay: (i) Unaggregated and disaggregated receptors are associated with a kinase that phosphorylates an exogenous (peptide) substrate but minimally, or not at all, the subunits of Fc epsilon RI or associated proteins (endogenous substrates). After aggregation, phosphorylation of the exogenous substrate is linear with time, but the modification of the endogenous substrates reaches a plateau, presumably because only those endogenous substrates that are adjacent to the kinase are phosphorylated. (ii) Aggregated receptors and disaggregated receptors have enhanced kinase activity toward exogenous substrate. The state of phosphorylation of the receptor correlates strongly with the yield of enhanced kinase activity. We propose that upon aggregation of Fc epsilon RI, a constitutively associated kinase phosphorylates endogenous substrates by transphosphorylation. As a result, additional kinase activity becomes manifest and this promotes further transphosphorylation. In view of the homology between Fc epsilon RI and other receptors central to the immune response, the latter receptors likely utilize a similar transphosphorylation mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.